RRCM
MNPR icon

Rappaport Reiches Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Rappaport Reiches Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,139
Closed -$7.81K – 115
2024
Q2 		$7.81K Hold
2,139
– – ﹤0.01% 99
2024
Q1 		$7.28K Hold
2,139
– – ﹤0.01% 103
2023
Q4 		$3.64K Hold
2,139
– – ﹤0.01% 84
2023
Q3 		$6.63K Hold
2,139
– – ﹤0.01% 73
2023
Q2 		$9.14K Hold
2,139
– – ﹤0.01% 77
2023
Q1 		$14.9K Hold
2,139
– – 0.01% 82
2022
Q4 		$25.3K Buy
+2,139
New +$26.1K 0.01% 79

Other funds holding MNPR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rappaport Reiches Capital Management's MNPR Position: Q3 2024 in Review

Rappaport Reiches Capital Management sold out of Monopar Therapeutics (MNPR) in Q3 2024, closing a stake of 2,139 shares — an estimated $7.81K sold.

Rappaport Reiches Capital Management first reported a position in MNPR in Q4 2022 and held it in 7 quarters. The position peaked at $25.3K in Q4 2022. 6 funds tracked by Wall St. Rank hold MNPR as of Q3 2024.

  • Rappaport Reiches Capital Management reported no remaining Monopar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Rappaport Reiches Capital Management sold 2,139 Monopar Therapeutics shares in Q3 2024, an estimated $7.81K.
  • Rappaport Reiches Capital Management first reported a position in Monopar Therapeutics in Q4 2022 and held it in 7 quarters.
  • Rappaport Reiches Capital Management's Monopar Therapeutics position peaked at $25.3K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2024.

Based on Rappaport Reiches Capital Management's 13F filing for Q3 2024, filed 9 Oct 2024.